Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.

ABSTRACT:

Background

Adoptive immunotherapy using T cells expressing chimeric antigen receptors (CARs) targeting CD19 has produced remarkable clinical outcomes. However, much of the mechanisms of action, such as the development of memory responses and sources of immune cytokines, remain elusive largely due to the challenge of characterizing human CAR T cell function in vivo. The lack of a suitable in vivo model also hinders the development of new CAR T cell therapies.

Methods

We established a humanized mouse (hu-mouse) model with a functional human immune system and genetically-matched (autologous) primary acute B-lymphoblastic leukemia (B-ALL) that permits modeling of CD19-targeted CAR T cell therapy in immunocompetent hosts without allogeneic or xenogeneic immune responses.

Findi

SUBMITTER: Jin CH 

PROVIDER: S-EPMC6354733 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature